Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2020 | Highlights in multiple myeloma at ASCO 2020

Suzanne Lentzsch • 29 May 2020
ASCO 2020
Multiple Myeloma
BOSTON GMMG-CONCEPT KarMMa StaMINA SWOG 1211

Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY, USA, takes us through a selection of the most important studies presented at ASCO 2020 in multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Suzanne Lentzsch

Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more
Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more
Suzanne Lentzsch • 3 May 2024
How to treat AL amyloidosis in 2020?
2:38
How to treat AL amyloidosis in 2020?
Suzanne Lentzsch • 31 Aug 2020
Chemotherapy-free approaches to AL amyloidosis
2:55
Chemotherapy-free approaches to AL amyloidosis
Suzanne Lentzsch • 27 Aug 2020
Unmet needs in amyloidosis
2:50
Unmet needs in amyloidosis
Suzanne Lentzsch • 1 Sep 2020

Related Videos

Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
4:13
Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
Suzanne Lentzsch • 7 Dec 2025
Key multiple myeloma breakthroughs at ASH 2025
6:04
Key multiple myeloma breakthroughs at ASH 2025
Suzanne Lentzsch • 7 Dec 2025
A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
4:18
A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
Suzanne Lentzsch • 7 Dec 2025
Ultra-deep WGS of cell-free DNA to detect bone marrow-derived mutations in multiple myeloma
2:29
Ultra-deep WGS of cell-free DNA to detect bone marrow-derived mutations in multiple myeloma
Suzanne Lentzsch • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals